Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis

被引:5
作者
Timmermann, Lea [1 ,2 ,3 ]
Rosumeck, Nathalie [2 ,3 ,4 ]
Klein, Fritz [1 ,2 ,3 ]
Pratschke, Johann [1 ,2 ,3 ]
Pelzer, Uwe [2 ,3 ,4 ]
Bahra, Marcus [1 ,2 ,3 ]
Malinka, Thomas [1 ,2 ,3 ]
机构
[1] Charite Univ Med Berlin, Dept Surg, Berlin, Germany
[2] Univ Berlin, Berlin, Germany
[3] Berlin Inst Hlth, Berlin, Germany
[4] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
关键词
Borderline resectable pancreatic cancer; BRPC; neoadjuvant chemotherapy; NAC; histopathological tumour stage; DUCTAL ADENOCARCINOMA; UPFRONT SURGERY; OPEN-LABEL; THERAPY; GEMCITABINE; CHEMORADIATION; FOLFIRINOX; CRITERIA;
D O I
10.21873/anticanres.13781
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Neoadjuvant chemotherapy (NAC) is established in the treatment of ductal pancreatic adenocarcinoma for downsizing borderline-resectable pancreatic cancer (BRPC) and may affect nodal positivity and rates of R0 resection. This study aimed to identify the impact of NAC on postoperative histopathological parameters with a prognostic relevance. Patients and Methods: A one-to-three matched-pair analysis, including an overall total of 132 patients (25% treated with NAC and subsequent resection and 75% undergoing upfront surgery) was performed. Influence of NAC on nodal positivity, lymphatic, vascular and perineural invasion, as well as resection stage and grading, was examined. Furthermore, perioperative complications, in-hospital stay, re-admission rates, mortality, as well as preoperative body mass index and American Association of Anesthesiologist classification scores, were evaluated. Results: Patients treated with NAC significantly less frequently had lymphatic tissue invasion (lymph node invasion: 51.5% vs. 72.7%; p=0.032, and lymphatic vessel invasion 9.4% vs. 55.3%; p=0.0004), whereas vascular and perineural invasion, as well as grading and resection state were not significantly different. Carbohydrate antigen 19-9 regression in correlation with nodal positivity also did not differ, and both groups showed comparable perioperative complication rates. Occurrence and severity of postoperative pancreatic fistula (18.2% vs. 24.3%; p=0.034) were significantly lower in patients who had undergone NAC. Conclusion: NAC significantly affects postoperative histopathological tumour stage in BRPC and appears to be a safe treatment option without increased perioperative complications, re-admission, in-hospital stay, or mortality. Further studies are mandatory to underline the suitability of NAC for ductal pancreatic adenocarcinoma subgroups in order to guide clinicians in their daily decision-making comprehensively.
引用
收藏
页码:5781 / 5787
页数:7
相关论文
共 23 条
[1]   Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS) [J].
Bockhorn, Maximilian ;
Uzunoglu, Faik G. ;
Adham, Mustapha ;
Imrie, Clem ;
Milicevic, Miroslav ;
Sandberg, Aken A. ;
Asbun, Horacio J. ;
Bassi, Claudio ;
Buechler, Markus ;
Charnley, Richard M. ;
Conlon, Kevin ;
Cruz, Laureano Fernandez ;
Dervenis, Christos ;
Fingerhutt, Abe ;
Friess, Helmut ;
Gouma, Dirk J. ;
Hartwig, Werner ;
Lillemoe, Keith D. ;
Montorsi, Marco ;
Neoptolemos, John P. ;
Shrikhande, Shailesh V. ;
Takaori, Kyoichi ;
Traverso, William ;
Vashist, Yogesh K. ;
Vollmer, Charles ;
Yeo, Charles J. ;
Izbicki, Jakob R. .
SURGERY, 2014, 155 (06) :977-988
[2]   Role of surgery in pancreatic cancer [J].
Buanes, Trond A. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (21) :3765-3770
[3]   Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm? [J].
Christians, Kathleen K. ;
Tsai, Susan ;
Mahmoud, Anna ;
Ritch, Paul ;
Thomas, James P. ;
Wiebe, Lauren ;
Kelly, Tracy ;
Erickson, Beth ;
Wang, Huamin ;
Evans, Douglas B. ;
George, Ben .
ONCOLOGIST, 2014, 19 (03) :266-274
[4]   FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer [J].
Conroy, T. ;
Hammel, P. ;
Hebbar, M. ;
Ben Abdelghani, M. ;
Wei, A. C. ;
Raoul, J. -L. ;
Chone, L. ;
Francois, E. ;
Artru, P. ;
Biagi, J. J. ;
Lecomte, T. ;
Assenat, E. ;
Faroux, R. ;
Ychou, M. ;
Volet, J. ;
Sauvanet, A. ;
Breysacher, G. ;
Di Fiore, F. ;
Cripps, C. ;
Kavan, P. ;
Texereau, P. ;
Bouhier-Leporrier, K. ;
Khemissa-Akouz, F. ;
Legoux, J. -L. ;
Juzyna, B. ;
Gourgou, S. ;
O'Callaghan, C. J. ;
Jouffroy-Zeller, C. ;
Rat, P. ;
Malka, D. ;
Castan, F. ;
Bachet, J. -B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2395-2406
[5]   Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients [J].
Dhir, Mashaal ;
Malhotra, Gautam K. ;
Sohal, Davendra P. S. ;
Hein, Nicholas A. ;
Smith, Lynette M. ;
O'Reilly, Eileen M. ;
Bahary, Nathan ;
Are, Chandrakanth .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2017, 15
[6]   Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey [J].
Dindo, D ;
Demartines, N ;
Clavien, PA .
ANNALS OF SURGERY, 2004, 240 (02) :205-213
[7]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[8]   Locally Advanced Pancreatic Cancer Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients [J].
Hackert, Thilo ;
Sachsenmaier, Milena ;
Hinz, Ulf ;
Schneider, Lutz ;
Michalski, Christoph W. ;
Springfeld, Christoph ;
Strobel, Oliver ;
Jaeger, Dirk ;
Ulrich, Alexis ;
Buechler, Markus W. .
ANNALS OF SURGERY, 2016, 264 (03) :457-463
[9]   Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer [J].
Hartwig, W. ;
Gluth, A. ;
Hinz, U. ;
Koliogiannis, D. ;
Strobel, O. ;
Hackert, T. ;
Werner, J. ;
Buechler, M. W. .
BRITISH JOURNAL OF SURGERY, 2016, 103 (12) :1683-1694
[10]   Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity Results of a Prospective Phase II Trial [J].
Heinrich, Stefan ;
Schaefer, Markus ;
Weber, Achin ;
Hany, Thomas F. ;
Bhure, Ujwal ;
Pestalozzi, Bemhard C. ;
Clavien, Pierre-Alain .
ANNALS OF SURGERY, 2008, 248 (06) :1014-1022